Xencor (XNCR) Cash from Investing Activities (2013 - 2026)
Xencor (XNCR) reported Cash from Investing Activities of $26.7 million for Q1 2026, up 95.18% year-over-year from $13.7 million in Q1 2025, and down 62.52% quarter-over-quarter from $71.2 million in Q4 2025.
Xencor (XNCR) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash from Investing Activities data on file, last reported at $26.7 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $26.7 million, up 95.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.0 million (up 676.86% YoY), and the FY2025 annual result was $140.0 million, up 1878.26% from the prior year.
- Cash from Investing Activities declined to $26.7 million in Q1 2026 per XNCR's latest filing, from $71.2 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $71.2 million in Q4 2025 and troughed at -$203.1 million in Q4 2023.
- A 5-year average of -$4.2 million and a median of $24.5 million in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 927.48% in 2023, then jumped 4798.65% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at $24.5 million in 2022, then tumbled by 927.48% to -$203.1 million in 2023, then jumped by 128.18% to $57.3 million in 2024, then rose by 24.32% to $71.2 million in 2025, then tumbled by 62.52% to $26.7 million in 2026.
- Business Quant data shows XNCR's Cash from Investing Activities at $26.7 million in Q1 2026, $71.2 million in Q4 2025, and $14.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 26.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.68 Mn |
| Mar 31, 2026 | 26.68 Mn |
| Dec 31, 2025 | 71.17 Mn |
| Dec 31, 2025 | 71.17 Mn |
| Sep 30, 2025 | 14.67 Mn |
| Sep 30, 2025 | 14.67 Mn |
| Jun 30, 2025 | 40.48 Mn |
| Jun 30, 2025 | 40.48 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Mar 31, 2025 | 13.67 Mn |
| Dec 31, 2024 | 57.25 Mn |
| Dec 31, 2024 | 57.25 Mn |
| Sep 30, 2024 | -163.46 Mn |
| Sep 30, 2024 | -163.46 Mn |
| Jun 30, 2024 | 66.02 Mn |
| Jun 30, 2024 | 66.02 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Dec 31, 2023 | -203.13 Mn |
| Dec 31, 2023 | -203.13 Mn |